Lv11
50 积分 2025-04-14 加入
A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects
3小时前
待确认
Diagnosis and Treatment of Chronic Lateral Ankle Instability: Review of Our Biomechanical Evidence
7个月前
已完结
Avulsion fracture of anterior talofibular ligament from talus: A case report
7个月前
已完结
A social network perspective on the Bamboo Ceiling: Ethnic homophily explains why East Asians but not South Asians are underrepresented in leadership in multiethnic environments
7个月前
已关闭
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial
7个月前
已完结
Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
7个月前
已完结
Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
7个月前
已关闭
Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
7个月前
已关闭
Demographics and clinical characteristics of metastatic colorectal cancer patients treated with bevacizumab-awwb in real-world oncology clinics
7个月前
已关闭
P-202 Demographics and clinical characteristics of metastatic colorectal cancer patients treated with a biosimilar to bevacizumab
7个月前
已关闭
皖公网安备34019202002308
